POELLATH advises Ventura BioMed Investors GmbH on VC investment in iQure Pharma Inc.
The round was led by Munich-based life science fund Ventura BioMed Investors and med-tech anchor investor OKG Capital. Both investors see this financing round as a first step towards additional funding to complete preclinical development and start Phase 1 trials.
iQure Pharma is a U.S.-based global biotech company specializing in the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases.
iQ-007 is an innovative therapeutic candidate for the treatment of epilepsy and other neurodegenerative diseases. The product has successfully completed the prestigious NIH-ETSP epilepsy screening program and pivotal tox studies are ongoing. The company plans to begin clinical development of iQ-007 in 2024.
in connection with the financing round, POELLATH provided comprehensive legal advice to Ventura BioMed Investors GmbH with the following team:
- Dr. Sebastian Gerlinger (partner, lead, M&A/VC, Munich)
- Markus Döllner (counsel, M&A/VC, Munich)
- Christine Funk (counsel, IP/IT, Frankfurt)
- Ludwig Niller (associate, M&A/VC, Munich)
